bc008
mAbexperimentalBi-specific
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 7, 2025 (NCT06773481)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
TIGIT inhibitor
- Programmed cell death protein 1INHIBITOR
PDCD1 inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06773507 | Phase 1 | May 12, 2025 | Chinese Academy of Medical Sciences, Shaanxi Buchang Pharmaceutical Co., Ltd |
| NCT06773481 | Phase 1 | Apr 7, 2025 | Capital Medical University, Shaanxi Buchang Pharmaceutical Co., Ltd |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shaanxi Buchang Pharmaceutical Co., Ltd | For profit | 2 | 2 | 1 | 2025 |
| Capital Medical University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2025 |
3 organizations
Page 1 / 1